



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Annual PCWP/HCPWP meeting with all eligible organisations

From relocation towards a business recovery pathway

20 November 2019

Noël Wathion
Deputy Executive Director

An agency of the European Union





Brexit impact on EMA's operations

- As of the beginning the aim was to operate “business as usual” as long as possible, while in parallel preparing for the Brexit consequences in terms of:
 - Impact on EMA operations
 - Physical move to a new host Member State



EMA business continuity planning (1/2)

- EMA developed a dedicated methodology by structuring first its activities in Cat 1 (highest priority), Cat 2 (medium priority), Cat 3 (lowest priority) activities
- As a next step, activities were temporarily suspended or scaled back, starting from Cat 3 activities
- An EMA BCP phase 1 was introduced as of 1 May 2017, the main objective of phase 1 being to free-up the necessary recourses to prepare for the consequences of Brexit
- Subsequent BCP phases (2 – 3 – 4) were introduced primarily to address staff loss that can not be compensated for through the recruitment of replacement resource



EMA business continuity planning (2/2)

- EMA is currently in BCP phase 4, which means that the Agency's focus is primarily on its core business (Cat 1 activities)
- In parallel a relocation BCP was introduced to cope with the physical relocation from London to Amsterdam in Q1 of this year



Next steps (1/2)

- A 2nd relocation BCP will be introduced, following the successful handover of the permanent EMA building on 15 November 2019, from 9 December 2019 to 10 January 2020, primarily to allow equipment and furniture to be moved to the final building, and to perform IT configuration and testing
- Although no face-to-face meetings will be held during that period (with the exception of the December Management Board meeting) normal operations will continue virtually throughout the whole period



Next steps (2/2)

- As the Agency is emerging from this period of transition, it is faced with the need to plan for business reinitiation of activities that have been placed on hold in BCP, with a reduced number of staff. In addition, important new demands have been placed on the Agency that will need to be prioritised, such as the implementation of new legislation for veterinary medicines and medical devices
- To make best use of available resources and be best prepared for future challenges, EMA is currently conducting an in-depth review of its organisation in a future-proofing exercise
- In defining its work programme for 2020 and beyond, EMA will focus on the core activities identified in the last phase of business continuity as a baseline and then prioritise additional activities dependent upon the available resources